Cardiovascular & Hematological Disorders-Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of in-depth/mini reviews, original research articles, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.
Hossein Vakili, Isa Khaheshi*, Amirsina Sharifi, Negin Nickdoost, Mohammad H. Namazi, Morteza Safi , Habibollah Saadat, Saeed A. Parsa, Mohammad A. Akbarzadeh, Mohammadreza Naderian, Negin Yousefi, Mahin Shirazi and Mohammadreza Tabary
Assessment of Admission Time Cell Blood Count (CBC) Parameters in Predicting Post-primary Percutaneous Coronary Intervention TIMI Frame Count in Patients with ST-segment Elevation Myocardial Infarction
Garry X. Shen University of Manitoba Winnipeg, MB (Canada) Biography
Biography of Garry X. Shen
Dr. Shen is the Professor in the Departments of Internal Medicine in the University of Manitoba. He graduated and received Master and Doctorial degrees from Shanghai Jiaotong University School of Medicine, and worked as physician in Shanghai Institute of Hypertension and Department of Cardiology in Shanghai Ruijin Hospital. He received postdoctoral training in University of Iowa, Cleveland Clinical Foundation, and University of Alberta. He has joined the Section of Endocrinology, Department of Internal Medicine, Faculty of Medicine in University of Manitoba since 1991 and promoted as Professor in 2006. His research program aims to mechanism and management of for diabetic cardiovascular complications and gestational diabetes. He published >100 peer reviewed papers and received a number of national and international awards and recognitions including Editor-in-Chief of Cardiovascular and Hematological Disorders-Drug Target, Advisory Professor in Shanghai Jiaotong University School of Medicine, and Councilor of Canadian Society of Atherosclerosis, Thrombosis and Vascular Biology.